Neurohormonal Modulation as a Therapeutic Target in Pulmonary Hypertension

García‐Lunar, Inés; Pereda, Daniel; Ibáñez, Borja; García‐Álvarez, Ana

doi:10.3390/cells9112521

Cited by 7 publications

(6 citation statements)

References 111 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…52 The autonomic nervous system is also involved in the pathogenesis of PAH, suggesting that this neurohormonal system can be regulated to treat PAH. 53 Besides CD248, there are other potential therapeutic targets for PAH such as miRNAs and spermidine. MiRNAs are non-coding singlestranded RNAs of approximately 22 nucleotides in length.…”

Section: Targeted Therapies For Pulmonary Arterial Hypertension (Pah)mentioning

confidence: 99%

Delivery System for Targeted Drug Therapy in Chronic Diseases

Jiang¹,

Chen²,

Yang³

et al. 2022

J Explor Res Pharmacol

View full text Add to dashboard Cite

Chronic diseases affect many people and have become the leading cause of death and loss of health worldwide. The etiology of chronic diseases is complex. They are usually incurable and require continual medical management. Many chronic diseases deteriorate with time, resulting in an enormous burden on society and patients' families. During the past years, targeted agents have made improved the management of various chronic diseases. An optimal drug delivery system can improve the therapeutic efficacy of these targeted drugs and reduce systemic adverse effects, bringing benefits for patients with chronic diseases. Here, we highlight recent research progress in the development of targeted therapeutic drugs for chronic diseases and improved delivery systems.

show abstract

Section: Targeted Therapies For Pulmonary Arterial Hypertension (Pah)mentioning

confidence: 99%

Delivery System for Targeted Drug Therapy in Chronic Diseases

Jiang¹,

Chen²,

Yang³

et al. 2022

J Explor Res Pharmacol

View full text Add to dashboard Cite

show abstract

“…PA denervation (PADN) targets directly the sympathetic stimulus over the pulmonary vasculature and has emerged as a promising therapeutical option for PH. During the past decade, multiple studies have been published both in the experimental field and clinical arena with controversial results (for an extensive review see a dedicated paper 124 ). Overall, a beneficial effect with PADN has been observed in experimental models of acute PH 125,126 and chronic PH induced by monocrotaline [127][128][129] , and also in patients with PAH.…”

Section: Pulmonary Arterial Denervationmentioning

confidence: 99%

Novelties in Pulmonary Hypertension Secondary to Left Heart Disease

Rodríguez-Arias¹,

Solé‐González²,

García‐Álvarez³

2022

BRN

Self Cite

View full text Add to dashboard Cite

Pulmonary hypertension due to left heart disease (PH-LHD) is the most common form of PH affecting approximately 1% of adults worldwide. Initially considered as just a passive consequence of increased pressure in the left chambers, new evidence shows the potential role of genetics, biological factors, or left atrial function. Along with the hemodynamic study, cardiac imaging techniques are essential to advance in the characterization of patients and select therapeutic strategies. Orphan of pharmacological treatments, new therapeutic targets are currently under investigation. The current review aims to review novelties in the fields of pathophysiology, diagnosis, and treatment in this entity.

show abstract

“…Therefore, many pharmacological and non-pharmacological interventions on the neurohormonal system have been investigated in preclinical and few clinical studies [8]. Nevertheless, translation from preclinical to clinical studies is difficult and is often lacking.…”

Section: Introductionmentioning

confidence: 99%

“…Nevertheless, translation from preclinical to clinical studies is difficult and is often lacking. Two recent reviews extensively described molecular pathways underlying the detrimental effects of neurohormonal activation [9] and pharmacological or invasive strategies targeting the neurohormonal system in PAH [8]. We wish to extend on this topic, and thereby provide future directions for research into the neurohormonal system in PAH.…”

Section: Introductionmentioning

confidence: 99%

Neurohormonal modulation in pulmonary arterial hypertension

et al. 2021

View full text Add to dashboard Cite

Pulmonary hypertension is a fatal condition of elevated pulmonary pressures, complicated by right heart failure. Pulmonary hypertension appears in various forms; one of those is pulmonary arterial hypertension (PAH) and is particularly characterised by progressive remodelling and obstruction of the smaller pulmonary vessels. Neurohormonal imbalance in these patients is associated with worse prognosis and survival. In this back-to-basics review on neurohormonal modulation in PAH, we provide an overview of the pharmacological and non-pharmacological strategies that have been tested preclinically and clinically. The benefit of neurohormonal modulation strategies in PAH patients has been limited by lack of insight in how the neurohormonal system is changed throughout the disease and difficulties in translation from animal models to human trials. We propose that longitudinal and individual assessments of neurohormonal status are required to improve timing and specificity of neurohormonal modulation strategies. Ongoing developments in imaging techniques such as positron emission tomography (PET) may become helpful to determine neurohormonal status in PAH patients in different disease stages and optimise individual treatment responses.

show abstract

Neurohormonal Modulation as a Therapeutic Target in Pulmonary Hypertension

Cited by 7 publications

References 111 publications

Delivery System for Targeted Drug Therapy in Chronic Diseases

Delivery System for Targeted Drug Therapy in Chronic Diseases

Novelties in Pulmonary Hypertension Secondary to Left Heart Disease

Neurohormonal modulation in pulmonary arterial hypertension

Contact Info

Product

Resources

About